U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07401875) titled 'A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)' on Feb. 05.
Brief Summary: To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The
Study Start Date: July 28, 2026
Study Type: INTERVENTIONAL
Condition:
Phase 1b
HC-7366
SHARK
Kidney Cancer
Intervention:
DRUG: Nivolumab
Given by IV
DRUG: HC-7366
Given by po
DRUG: ipilimumab
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Disclaimer: Curated by HT Syndication....